Hugo is about to joust da Vinci. It’s not a battle between Renaissance geniuses. Instead, a commercial fight is brewing ...

Ryan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned ...

Medtronic plc is rated a Buy, expecting 10-11% annual total returns, supported by 7-8% EPS growth. Learn more about MDT stock ...

Even if that will be an important step for Medtronic, Intuitive Surgical should remain the top player and still outpace its challenger. For one, it will take a long time for Medtronic's Hugo to earn ...

Medtronic's fair value estimate has nudged higher to $111.05 from $109.82 as analysts grow more confident that the company ...

Liberant is indicated for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous ...

Weispfenning has more than 25 years of experience at Medtronic, joining its IR team 17 years ago. He led the function at the ...

Medtronic announced the first commercial use of the Liberant thrombectomy system, which is indicated for the removal of fresh, ...

With the U.S. authorization for urologic procedures, “there is now choice” for hospitals that want to expand their robotic ...

Though the Medtronic OmniaSecure is the world's smallest defibrillation lead, the product development story isn't one of ...

Is it too late to invest in the stock now that it's gained 23% this year? Let's find out whether Medtronic's shares are a buy heading into 2026. During the second quarter of its fiscal year 2026, ...

Medtronic issues recall diabetes software affecting CareLink version 4.2B due to incorrect glucose data display, prompting clinician review.